TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03205202

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Study: NCT00054847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous vein graft
Description: Saphenous vein harvested from the arm is used as a conduit for CABG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery graft
Description: Radial artery harvested from the arm is used as a conduit for CABG.
Study: NCT03495492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Chelation
Description: Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Therapy
Description: Vitamins and minerals that will be taken one or more times a day.
Study: NCT04673981

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnostic tes for neuropathic pain
Description: Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
Study: NCT03812406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: French Abulatory Cesrean Section
Description: A cesarean section performed according to the FAUCS technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Misgav-Ladach
Description: A cesarean section performed according to the Misgav Ladach technique
Study: NCT04035876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Description: Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
Study: NCT01438645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus ScopeGuide
Description: ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
Study: NCT04436302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergame device
Description: motor-cognitive training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame device
Description: motor-cognitive training
Study: NCT01316042

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: 2 pills per day for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, glucophage
Description: 2 212.5mg pills/day for 12 months
Study: NCT03044392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Next Bolus Interval
Description: Next Bolus Interval 15, 30, or 45 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Next Bolus Interval
Description: Next Bolus Interval 15, 30, or 45 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Next Bolus Interval
Description: Next Bolus Interval 15, 30, or 45 minutes
Study: NCT01340183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5099
Description: IV Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Dose
Study: NCT00289640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab (MDX-010, BMS-734016)
Description: IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study: NCT01597947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-975
Description: Intravenous single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous single dose
Study: NCT01969266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: PCI-32765
Description: 840 mg capsule formulation administered by mouth on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: PCI-32765
Description: 840 mg solution formulation administered by mouth on Day 1
Study: NCT01767584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Reference product
Study: NCT01875952

Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid
Description: Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
Study: NCT01767584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 1g tablets
Description: Test product
Study: NCT03228368

Intervention type: DRUG
Intervention: Atezolizumab (MPDL3280A)
Description: anti-programmed death-ligand 1 (PD-L1) antibody
Study: NCT00640094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: melatonin
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
Study: NCT03471455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
Study: NCT01357213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 3AB
Description: Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 100 ml
Study: NCT02495337

Intervention type: OTHER
Intervention: Tissue Collection
Study: NCT01009528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic feedback system on diabetes care
Description: An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
Study: NCT01800188

Intervention type: PROCEDURE
Intervention: Hemodialysis
Description: A 4 hour hemodialysis with a standardized liquid meal after one hour

Intervention type: PROCEDURE
Intervention: Hemodiafiltration
Description: A 4 hour hemodiafiltration with a standardized liquid meal after one hour

Intervention type: PROCEDURE
Intervention: Meal test
Description: A 3 hour standardized liquid meal test without dialysis
Study: NCT00437658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Provided as tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Provided as tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Description: Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Elagolix
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DMPA-SC
Description: Matching placebo for subcutaneous injection in a pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DMPA-SC
Description: Matching placebo for subcutaneous injection in a pre-filled syringe
Study: NCT00379327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture administered in last three weeks of pregnancy
Study: NCT02830516

Intervention type: OTHER
Intervention: Measurement of lung elastance by two methods
Description: Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
Study: NCT00905346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg Capsules
Description: Topiramate Capsules 2 x 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® 25 mg Capsules
Description: Topamax® Capsule 2 x 25 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Applesauce
Description: Applesauce

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applesauce
Description: Applesauce
Study: NCT00379327

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-puncturing Acupuncture Needle
Description: Streitsberg non-Acupuncture Needle
Study: NCT01602653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Description: an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK
Description: an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
Study: NCT04664621

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HepQuant
Description: Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
Study: NCT02325531

Intervention type: OTHER
Group type: OTHER
Intervention: Low support
Description: EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows

Intervention type: OTHER
Group type: OTHER
Intervention: Medium support
Description: Same as provided to the low support arm, PLUS~* STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~* ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 \& 3.

Intervention type: OTHER
Group type: OTHER
Intervention: High support
Description: Same as provided to the low and medium support arms, PLUS~- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison
Description: No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
Study: NCT00928525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
Study: NCT06391606

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 2 pills/day of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills/day
Study: NCT02372305

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FlexHD
Description: Patients will be randomized to receive FlexHD.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: Patient will be randomized to receive Alloderm.
Study: NCT02769715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-sintered removable partial denture
Description: The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cast removable partial dentures
Description: The denture was fabricated traditionally using lost-wax casting technique.
Study: NCT04212000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole tablet
Study: NCT02305706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: starting position in colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: starting position in colonoscopy
Study: NCT03884088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limits of Stability
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limits of Stability
Description: Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
Study: NCT04212000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole tablet
Study: NCT04271761

Intervention type: OTHER
Intervention: Non-interventional, post-market, pilot study of Carina Cochlear System
Description: Several objective acoustic measurements will be performed that do not require active participation from the subject.
Study: NCT03170622

Intervention type: DIAGNOSTIC_TEST
Intervention: Intervention group
Description: This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
Study: NCT03365115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100 mcg will be injected.
Study: NCT02357511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Monitor used
Study: NCT01573312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASO3 Adjuvant
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
Study: NCT03494556

Intervention type: OTHER
Intervention: Data Collection
Description: Paramedic will use data collected during routine care to complete four risk stratification tools.
Study: NCT00883493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate XR
Description: Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate XR
Description: Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
Study: NCT00756548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI850
Description: multi-dose preparation for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350 based bowel preparation
Description: multi-dose preparation for oral administration prior to colonoscopy
Study: NCT03837184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
Study: NCT02983604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5829
Description: Tablet(s) administered orally once daily
Study: NCT03365115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100 mcg will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal fentanyl
Description: Intrathecal fentanyl 25 mcg will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Description: Intrathecal fentanyl 25 mcg will be injected.
Study: NCT00719745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR4
Description: oral
Study: NCT03075553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01209390

Intervention type: DEVICE
Intervention: Chondromimetic
Description: The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate.
Study: NCT04694391

Intervention type: GENETIC
Intervention: whole exome sequence
Description: To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.

Intervention type: GENETIC
Intervention: whole exome sequence
Description: To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
Study: NCT04472156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfer of mosaic embryo
Description: Subjects will transfer a mosaic embryo transferred to their uterus
Study: NCT02983604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5829
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5829
Description: Tablet(s) administered orally once daily
Study: NCT00818545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ER4017 (hydroxypropyltetrahydropyrantriol)
Description: Cream, 10%, each day during 3 months
Study: NCT00591110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye care education
Description: Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
Study: NCT02983604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
Study: NCT00591110

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social-contact control
Description: Participants receive an engaging informational session on a non-health related topic
Study: NCT03020446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbion Dressing
Description: Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
Study: NCT04357301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop vasopressor
Description: The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
Study: NCT00647829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth for 2 doses over a 24-hour period